Sign in
Taking people in SpainPhase 2

Tests darolutamide added to standard treatment for advanced prostate cancer

Tests darolutamide with standard care in men with advanced prostate cancer.

Key facts

Who runs it
Swiss Group for Clinical Cancer Research
Where
Barakaldo, Barcelona, Cáceres, Castello De La Plana, Córdoba, Lugo, Madrid, Oviedo, Palma, Pamplona, Sabadell, Salamanca, San Sebastián de los Reyes, Sevilla, Toledo, Valencia, and Valladolid, SpainSee the 20 sites
Registry title
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
6 Aug 2025
Expected to end
1 Jul 2030
Type of study
Interventional
Record updated
12 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. They have not yet had treatment for this stage. It tests adding darolutamide to standard care.

Age
18 years or older
Sex
Men only
Disease stage
Prostate adenocarcinoma that has spread (metastatic) and keeps growing despite castration (mCRPC); spread shown on imaging
Earlier treatment
Must have responded to an ARPI for at least 12 months in the hormone-sensitive stage. Must stay on GnRH analogues during the trial unless surgically castrated. Must not have had other systemic treatment for the castration-resistant stage.

Main reasons for not taking part

  • A small cell component in the tumour
  • Prior LuPSMA or radium 223 for prostate cancer
  • Prior chemotherapy for the hormone-sensitive stage, except docetaxel
  • Severe or uncontrolled heart or blood vessel disease
  • Current spinal cord compression

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
  • Castration resistance: tumor progression after orchiectomy or during treatment with GnRH analogues (agonists or antagonists)
  • Non-surgically castrated patient agrees on ongoing use of GnRH analogues (agonists or antagonists) during the trial
  • Metastatic disease, documented by imaging according to PCWG3 criteria
  • Prior response to ARPI for at least 12 months in the mHSPC setting
  • Adequate bone marrow, hepatic and renal functions

Who cannot take part

  • Prior systemic therapy for metastatic castration-resistant disease
  • Prior chemotherapy for mHSPC, except docetaxel
  • Prior LuPSMA or radium 223 for prostate cancer
  • Concomitant use of other anti-cancer drugs or radiotherapy except for local pain control and GnRH analogues
  • Any concomitant drugs contraindicated for use with darolutamide or known hypersensitivity to darolutamide
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of darolutamide
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications
  • Severe or uncontrolled cardiovascular disease
  • Acute exacerbations of chronic illnesses, serious infections, or major surgery before start of treatment
  • Presence of a small cell component
  • Clinical or radiological evidence of current spinal cord compression

Where in Spain

  • Hospital Universitario de CrucesBarakaldo, SpainTaking people
  • Hospital Clinic de BarcelonaBarcelona, SpainTaking people
  • Hospital del MarBarcelona, SpainTaking people
  • Hospital San Pedro De AlcántaraCáceres, SpainTaking people
  • Consorcio Hospitalario Provincial De CastellonCastello De La Plana, SpainTaking people
  • Hospital Universitario Reina SofiaCórdoba, SpainTaking people
  • Hospital Universitario Lucus AugustiLugo, SpainTaking people
  • Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
  • Hospital Universitario HM SanchinarroMadrid, SpainTaking people
  • Hospital Universitario Puerta de Hierro de MajadahondaMadrid, SpainTaking people
  • Hospital Universitario Central De AsturiasOviedo, SpainTaking people
  • University Hospital Son EspasesPalma, SpainTaking people
  • Hospital Universitario de NavarraPamplona, SpainTaking people
  • Parc Tauli Hospital UniversitariSabadell, SpainTaking people
  • Hospital Universitario De SalamancaSalamanca, SpainTaking people
  • Hospital Universitario Infanta SofiaSan Sebastián de los Reyes, SpainTaking people
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
  • Hospital Universitario de ToledoToledo, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
  • Hospital Clínico Universitario de ValladolidValladolid, SpainTaking people

About the trial

What the trial wants to find out

The main objective is to assess the efficacy of darolutamide, used in addition to physician-choice standard of care and then in maintenance therapy, on radiographic progression-free survival (rPFS) for patients in the first line setting of mCRPC.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
Plain-language title
Tests darolutamide added to standard treatment for advanced prostate cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 June 2026